Press Release: NeuroTherapia : NeuroTherapia Announces EMA Approval of its Phase 2 Trial for the Treatment of Alzheimer's Disease

NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial.